Current Advances in mRNA Vaccines for Infectious Diseases and Cancer Immunotherapy
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".
Deadline for manuscript submissions: 31 July 2025 | Viewed by 4083
Special Issue Editor
Special Issue Information
Dear Colleagues
mRNA vaccine technology has proven to be an effective medical countermeasure against the COVID-19 pandemic. Over the past two decades, mRNA research labs have dedicated their efforts to gaining a better understanding of this innovative technology. One advantage of mRNA vaccines is their increased safety profile due to the short-lived nature of RNA and the lower risk of integration into the recipient's DNA. However, mRNA’s stability may limit its use in infectious diseases and cancer. Implementing innovative approaches to the mRNA platform is important to increase its applications for viruses, cancer, or other diseases for which no valid therapeutics are available.
This special issue explores various research areas, such as mRNA structure and stability, different administration routes, the use of adjuvants in mRNA technology, and the application of self-amplifying mRNA-based vaccines. Additionally, considerations on the mechanisms of mRNA vaccine that induce cell-mediated innate and humoral immunity are welcome, as are discussions on ex vivo platforms such as organoids and organ-on-chip systems to study mRNA vaccination.
Dr. Sushma M. Bhosle
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mRNA design
- vaccines
- infectious disease
- cancer immunotherapy
- self-amplifying mRNA
- adjuvants
- organ-on-chip
- mRNA stability
- immune response
- clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
